July 24 (Reuters) – A panel of outside advisers to the U.S. FDA on Friday voted to exclude peptide emideltide from a list that would allow broader pharmacy compounding.
Read more House Sends Flurry of Bills to Senate Before Summer Recess
Seven members voted against recommending emideltide to be on the list, while six members voted in favor. One member abstained.
Read more European Commission Gives Guarded Welcome to New Trump Tariffs
(Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)
Copyright 2026 Thomson Reuters.
